OrganiGram Holdings Inc OTCMKTS: OGRMF Receives Perimeter License Amendment for Phases 4A and 4B as well as Initial 13 Cultivation Rooms in Phase 4A

JOHNSTOWN, NY - AUGUST 19: Rows of cannabis plants grow in the twenty thousand square foot greenhouse at Vireo Health's medical marijuana cultivation facility, August 19, 2016 in Johnstown, New York. New York state lawmakers voted to legalize marijuana for medical use in 2014 and the law took effect in January 2016. Currently, five organizations are allowed to grow and sell the drug for medical use in the state. New York's new law only allows people with 'severe debilitating or life threatening conditions' to obtain marijuana for medical use. (Photo by Drew Angerer/Getty Images)

OrganiGram Holdings Inc OTCMKTS: OGRMF is a TSX Venture Exchange listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada.

Organigram is focused on producing the highest-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada).
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

OrganiGram Holdings Inc OTCMKTS: OGRMF On April 30, 2019 Organigram Holdings Inc., the parent company of Organigram Inc. (the “Company” or “Organigram”), a leading licensed producer of cannabis is pleased to announce that it has received an expanded cultivation license from Health Canada in line with its previously announced Phase 4A and 4B expansion plans for its Moncton Campus.

The scope of the amendment includes approval of the following:

Perimeter Expansion Licensed – Representing an additional 163,000 sq ft of allocated space for 63 cultivation rooms populating the Company’s planned Phase 4A and 4B expansion, including the initial 13 cultivation rooms now approved. The approval of the perimeter for Phase 4B was received ahead of schedule, in tandem with the approval for Phase 4A.

13 Incremental Cultivation Rooms – Representing 11,000 kg of immediate increased target production capacity. The remaining 18 Phase 4A cultivation rooms can now be submitted for Health Canada review.
Mechanical Room – Built to support all 63 cultivation rooms included in the Company’s planned Phase 4A and 4B expansion. The mechanical room houses Organigram’s state-of-the-art irrigation and water reclamation systems.
Additional Storage Area (Building C) and Processing Space – Built in anticipation of the Company’s future requirements for storage and processing relative to both dried cannabis and cannabis derivative products.

As a result of this approval, cannabis plants will be moved into these new rooms on a rolling basis in early May. The Company anticipates being able to harvest product from these new rooms by the end of July, based on normal cultivation timelines. Subsequent Health Canada licensing amendment submissions will follow to allow for a continuous filling of the remaining 50 Phase 4 cultivation rooms (4A (18 rooms) and 4B (32 rooms)) mirroring the successful approach utilized with the Company’s Phase 2 and 3 expansions.

“We are proud to continue our legacy of delivering on our commitments” says Greg Engel, CEO, Organigram. “The completion of this phase of our expansion reinforces our commitment to innovation, efficiency and best-in-class operations. Being on time, this expansion reinforces our commitment to shareholders and shows our abilities with industry-leading execution.”

The full Phase 4 expansion represents an aggregate of 77,000 kg of additional annual capacity and is being completed in a series of stages (4A: 26,000 kg; 4B:27,000 kg; and 4C: 24,000 kg) which, once fully licensed and operational, is expected to bring the Company’s annualized target production to approximately 113,000 kg by the end of calendar 2019.

A Phase 5 refurbishment is also underway for an edibles and derivative facility and additional in-house extraction capacity.

“Our stalwart commitment to our customers is reflected in our ongoing investment in exceptional processes and delivering exceptional products,” says Engel.